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ABSTRACT
MicroRNAs (miRNAs) target mRNAs in human cells
via complex mechanisms that are still incompletely
understood. Using anti-Argonaute (anti-AGO)
antibody co-immunoprecipitation, followed by
microarray analyses and downstream bioinformat-
ics, ‘RIP-Chip’ experiments enable direct analyses
of miRNA targets. RIP-Chip studies (and parallel
assessments of total input mRNA) were performed
in cultured H4 cells after transfection with miRNAs
corresponding to the miR-15/107 gene group
(miR-103, miR-107, miR-16 and miR-195), and five
control miRNAs. Three biological replicates were
run for each condition with a total of 54 separate
human Affymetrix Human Gene 1.0 ST array repli-
cates. Computational analyses queried for deter-
minants of miRNA:mRNA binding. The analyses
support four major findings: (i) RIP-Chip studies
correlated with total input mRNA profiling provides
more comprehensive information than using either
RIP-Chip or total mRNA profiling alone after miRNA
transfections; (ii) new data confirm that miR-107
paralogs target coding sequence (CDS) of mRNA;
(iii) biochemical and computational studies indi-
cate that the 30 portion of miRNAs plays a role in
guiding miR-103/7 to the CDS of targets; and
(iv) there are major sequence-specific targeting dif-
ferences between miRNAs in terms of CDS versus
30-untranslated region targeting, and stable AGO as-
sociation versus mRNA knockdown. Future studies
should take this important miRNA-to-miRNA vari-
ability into account.
INTRODUCTION
MicroRNAs (miRNAs) are non-coding regulatory RNA
comprising  22nt. In all known animals, miRNAs guide
Argonaute (AGO)-containing microribonucleoprotein
(miRNP) complexes to target mRNAs (1). Important
questions remain about how miRNAs’ nucleotide se-
quences relate to their biological functions. A handful of
miRNAs are entirely conserved throughout all metazoan
species and dozens of different miRNAs are conserved
among vertebrates (2), which indicate that the entire
length of these miRNAs must be serving important func-
tions. However, the mechanisms for miRNA:mRNA
binding are complex and incompletely understood. The
importance of the miRNA ‘50 seed’—nucleotides 2–7
from the 50-end of the miRNA—in terms of mRNA tar-
geting has been sustained consistently (3). Also, the 30 un-
translated region (30-UTR) of mRNAs has been shown to
be an important context for targeting by some miRNAs
(4). However, it is mistaken to assume that every
miRNA’s target repertoire is characterized by a 50 seed
of a miRNA interacting with target mRNA 30-UTR (5–7).
A promising method for directly characterizing
miRNPs is co-immunoprecipitation (co-IP) that pulls
down AGO proteins along with associated molecules
(8–10). Using AGO co-IP assays, researchers have
isolated multiple proteins, miRNAs and mRNA targets
from miRNPs (11–17). A subset of AGO co-IP experi-
ments involve ‘RIP-Chip’ techniques (18,19) that integrate
miRNP co-IP with downstream high-density microarrays.
This assay enables high-throughput assessment of
AGO-associated mRNA for the systematic study of
target mRNAs.
RIP-Chip assays were used previously to study why par-
ticular mRNAs get recruited into miRNPs after miRNA
transfections. The monoclonal antibody (‘anti-AGO’,
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AGO2 (product of the gene EIF2C2), and recognizes a
C-terminal AGO2 epitope (20). Applying RIP-Chip to
H4 glioneuronal cell line (21) enabled the evaluation of
some of the sequence determinants of miRNA:mRNA
interactions (19). Experimentally validated miR-107
targets, unlike targets of some other miRNAs, tend to
have sequences complementary to miR-107 in the target
mRNAs’ open reading frame/coding sequence (CDS),
rather than the 30-UTR (10,19,22). MiR-107 is a
member of a group of genes that are highly expressed in
virtually all known mammalian cells (23) and prior studies
did not evaluate other members of this miRNA group
systematically. Nor is it known whether the 30 portion of
miR-107 plays a role in guiding the miRNA to
experimental-veriﬁed mRNA targets.
Here, we performed a series of new experiments
studying the miR-15/107 group of miRNAs, attempting
to better understand the implications of both 50 and 30
portions of miRNA in terms of mRNA targeting. We
analyzed both the putative target mRNAs that are
associated with AGO in the RIP-Chip, and also those
mRNAs downregulated following miRNA transfections.
These experiments have provided further data about
miRNA:mRNA functions and targeting mechanisms.
MATERIALS AND METHODS
Transfections, Co-IP of miRNPs using anti-AGO
antibodies
The Anti-AGO RIP-Chip methodology has been
validated and described in detail (19). Transfections with
‘Pre-miR’ reagents (Ambion) were performed exactly as
previously described in detail (24). RNA was extracted
using Trizol LS (Invitrogen, Carlsbad, CA, USA) as
described (25).
Transfections with miR-107 duplex RNA
Hsa-miR-107 guide and passenger strands sequences from
mirBase (26) and the mature sequences were synthesized
(Integrated DNA Technologies). For annealing,
equimolar concentrations of the guide and passenger
strands (100pmol/ml) were mixed in annealing buffer,
heated to 75 C for 5min, and cooled at 37 C for 1h and
then stored at  20 C until needed. Transfections were
performed identically as described above with the
Ambion siRNA-like reagents. RT–qPCR reactions for
BACE1 and GRN mRNA were performed exactly as
described previously (24).
Microarray analysis and RT–qPCR and downstream
data analyses
Microarray analysis of RNAs isolated from co-IP or from
total lysates were performed using Affymetrix Human
Gene 1.0 ST
TM chip at the University of Kentucky
Microarray Core Facility as described previously (19,22).
Three biological replicates were carried out in each treat-
ment. Similarity matrix data were prepared using the
Partek Genomics Suite. Other ﬁgures show results of
Log2 microarray values. Criteria for selecting PmiTs ac-
cording to anti-AGO RIP-Chip data (based on the
averaged results of the three biological replicates on the
array data for each transfection condition) were as
follows: (i) the mRNA was enriched in the AGO-
miRNPs after the cells were transfected with a particular
miRNA, relative to the negative control miRNA; and (ii)
the same mRNA was not upregulated >2-fold in the lysate
after transfection with the miRNA.
Following the identiﬁcation of PmiT-AGOs using these
criteria, the 50-UTR, CDS, and 30-UTR sequences were
analyzed for 6-mer sequences correlating to portions of
the miRNAs (in anti-sense and sense orientation), and
compared to the control sequences as follows.
For each PmiT, the 50-UTR, CDS and 30-UTR sequence
regions were analyzed separately. For each sequence
region of a PmiT, 200 control sequences from
non-PmiTs were selected based on sequence length.
Speciﬁcally, the selected sequences (50-UTR, CDS or
30-UTR from non-PmiTs) had the closest length match
to the corresponding sequence regions from the PmiT.
Then from this pool of 200 sequences, 20 were randomly
selected as negative controls for the PmiT in consider-
ation. Thus, for 100 PmiTs, there were 2000 combined
control sequences for 50-UTR, CDS or 30-UTR,
respectively.
Identiﬁcation of sequence motifs in PmiTs corresponding
to the 30 portion of miRNAs
We analyzed miR-107/103 and two mutated miRNAs
derived from miR-107 (MUT1 and MUT2) to identify
potentially enriched words in PmiTs corresponding to
the 30 portion of these miRNAs. In this analysis,
putative transcript targets, as identiﬁed in either the
anti-AGO co-IP or lysate fraction, were included to
identify pentamer words that match to any pentamer
sequence from the last 12nt of the cognate miRNA. To
reduce the background noise of unrelated pentamer
matches from the whole-target transcript sequence, the
matching pentamer words were required to reside within
the putative target site, deﬁned as 2–30-nt downstream of
the predicted seed-binding site. For each miRNA, the
number of target transcripts with a matching pentamer
in the target site was identiﬁed and listed in Tables 2 or
3. Simulation tests were performed to evaluate the statis-
tical signiﬁcance of the observed motif enrichment. A
separate simulation test was performed for each
miRNA. In each simulation test, 10000 runs were per-
formed to identify pentamer words within the putative
target sites that matched to a randomized 30-end
sequence of the cognate miRNA. The P-value was
calculated by counting the percentage of simulation runs
in which at least a threshold number of target transcripts
had matching pentamers to the randomized 30-end
sequence.
RESULTS
The study design is indicated schematically in Figure 1.
The putative miRNA targets (PmiTs) were experimentally
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Anti-AGO co-IP following miRNA transfections
(PmiT-AGO) and mRNAs downregulated in the cell
lysate following miRNA transfection (PmiT-Lys).
Transfected miRNAs are shown in Figure 2. In this
study, the ‘mRNA levels’ indicate the mean signal
intensities read from the Affymetrix Human Gene 1.0
ST
TM chip for each transcript (mean results from three
different biological replicates each). After transfection
with a speciﬁc miRNA, the designated PmiTs had
increased mRNAs in the Anti-AGO RIP-Chip
(PmiT-AGO), or decreased mRNA levels in the total
RNA from cell lysates (PmiT-Lys), relative to the same
mRNA levels following transfections with a negative
control miRNA (NEG-CTRL, also transfected with
three biological replicates, Figure 2). The data for PmiTs
are presented in Supplementary Table S1.
The microarray data indicated consistent results follow-
ing miRNA transfections, both in the anti-AGO co-IP and
in the cell lysates. A similarity matrix for the raw data
analyzing the anti-AGO RIP-Chip microarray results are
analyzed with a similarity matrix as shown in
Supplementary Figure S1. Only a single sample, one of
the control transfections (miR-15b*) had a relatively
low degree of similarity with the other samples. These
data indicate a relatively high degree of correlation for
all biological replicates, presumably indicating that most
mRNAs are not miRNA targets for a given miRNA.
Microarray data from the total lysate mRNAs had com-
parable between-replicate ﬁndings (data not shown). For
complete data from all the experiments, see
Supplementary Figure S1.
The data quality can be assessed further by analyzing
the putative target (PmiT-AGO) mRNAs. The top 100
PmiT-AGO mRNAs for miR-107 and miR-103 are
compared in Supplementary Figure S2. The potency of
individual PmiT-AGO targets is judged based on the
mean ratio of the mRNA signal on the microarray from
anti-AGO RIP-Chip following transfection with each
miRNA, to the signal for the same mRNA following
transfection with the NEG-CTRL (Figure 2). The top
100 PmiT-AGO mRNAs of miR-103 and miR-107 were
very similar (Supplementary Figure S2; R
2 correlation co-
efﬁcient is 0.769). In contrast, there is no similarity of top
100 PmiTs among those mRNAs enriched in the miRNP
following miR-320 transfections (R
2<0.001).
Another assessment of data quality was to ascertain
whether the miR-107 results in these new experiments
replicated prior studies (19,22). Previously, miR-107 trans-
fection caused both BACE1 mRNA and GRN mRNA to
be downregulated in cell lysates. However, of these two
transcripts, only GRN mRNA was enriched in the
anti-AGO co-IP after miR-107 transfection. Results
in the current dataset are shown in Supplementary
Figure S3. These data show the same ﬁndings as described
previously. A potential confounder in both this and prior
studies from our laboratory is that we use the Ambion
‘Precursor’ reagents. These RNA complexes are actually
similar to an siRNA (perfect duplex) and raise the possi-
bility that our data are epiphenomena related to the
perfect (non-physiological) duplex conformation. To
control for this, we performed an additional experiment
with an imperfectly paired duplex that more faithfully re-
capitulates the physiological mature miR-107 duplex
(Supplementary Figure S4). We then performed anti-
AGO co-IP and then RT–qPCR for both BACE1 and
Day 0
Transfect cells Downstream
with miRNAs Day 2
(N=3 reps each)
Lysate
Anti-Argonaute
bound to beads
in centrifuge tube
Ago
Co-IP
H4 cells
￿ RNA isolation
(lysates & Co-IPs
in parallel; 3 each)
￿ High-density 
Affymetrix array
(mRNA profiles)
￿ Bioinformatics
Experimental Design: Anti-AGO RIP-Chip
6nt seed
miRNA
mRNA
Assess miRNA/mRNA 
seed sequence frequencies 
(in 5’UTR, CDS, and 3’UTR)
after specific miRNA transfections
AGO Co-IPs              Lysate total RNA 
(Ago-bound mRNA)             (Knocked-down mRNA)
Putative miRNA Target (PmiT) criteria
PmiT-AGO PmiT-Lys
Increase Co-IP mRNA               Decrease lysate mRNA
after miRNA transfection after miRNA transfection
vs Co-IP mRNA after  vs lysate mRNA after
NEG-CTRL miRNA transfection          NEG-CTRL miRNA transfection
Figure 1. Experimental design of miRNA transfection experiments
followed by anti-AGO co-immunoprecipitation (anti-AGO Co-IP)
and microarray proﬁling of mRNAs from the anti-AGO Co-IP and
lysates. Downstream bioinformatics allowed comparison between the
mRNA ‘targets’ seen in the RIP-Chip experiments, relative to the
mRNAs ‘knocked down’ in the lysates following miRNA transfections.
miR-103 
miR-107 
miR-107 MUT1 
miR-107 MUT2 
miR-15b*
miR-16
miR-195
miR-320
NEG-CTRL
Transfected miRNAs
5’seed sequence
(miRNA nts #2-7)
Figure 2. List of miRNAs transfected in the current study. The 50 seed
sequence (nucleotides 2–7) of the miRNAs is indicated. Note that there
are three non-physiological controls—miR-107 MUT1, miR-107 MUT2
and NEG-CTRL. miR-15b* is an anti-sense control miRNA. Note that
four members of the miR-15/107 gene family of miRNAs (miR-16,
miR-195, miR-103 and miR-107) have similar 50-seed sequences.
Nucleic Acids Research, 2011,Vol.39, No. 18 8165GRN mRNA. As with the perfectly paired siRNA-like
miRNA transfection reagents, the more physiological
mature miRNAs had the same pattern with abundant
enrichment for GRN, but not BACE1 mRNA in the
anti-AGO RIP (Supplementary Figure S4D). An add-
itional list is provided of the 20 mRNAs that are most
knocked down in cell lysate following miR-107 transfec-
tion, but are not enriched in anti-AGO co-IP, as with
BACE1 (Supplementary Table S2).
We next tested whether a sequence corresponding to the
‘50 seed’ (Figure 2) for each transfected miRNA is enriched
in the 50-UTR, CDS and 30-UTR from the miRNAs’
target mRNAs. The top 100 PmiT-AGOs of each
miRNA were analyzed for miRNA seed sequences in
50-UTR, CDS and 30-UTR. The seed densities (number
of anti-sense 50 seed sequences per 1000nt) for the top
100 PmiT-AGOs—in 50-UTR, CDS and 30-UTR—were
compared to a control group of 2000 length-matched
randomized non-PmiT mRNAs (see ‘Materials and
Methods’ section for control sequence selection). The
same comparative analysis was repeated 10 times by
choosing different sets of length-matched randomized
control sequences, and the results from the ten rounds
were averaged and presented in Table 1. In addition,
more details regarding sequence length and seed count
of the PmiT-AGOs are summarized in Supplementary
Table S3.
Table 1 shows that among PmiT-AGO mRNAs, there is
consistent enrichment of 6-mer sequences complementary
to a transfected miRNAs’ 50 seed portion, and these se-
quences tended to be present in the CDS and 30-UTR.
Intriguingly, the degree of enrichment in the CDS and
30-UTR seems to be different for particular transfected
miRNAs. For example, for both miR-103 and miR-107,
the ratio of CDS enrichment to 30-UTR enrichment (in
terms of nucleotides 2–7 seed sequences/1000nt) is above
1.6. In contrast, for miR-320, the ratio of CDS enrichment
to 30-UTR enrichment is 1.07. The difference was startling
for the miR-107 mutant (non-physiological) miRNAs—
the ratio of CDS enrichment: 30-UTR enrichment was
2.43 for MUT1 (mutated 50 seed), but only 0.75 for
MUT2 (mutated 30 portion).
The data in Table 1 indicate that the presence or
absence of the 30 portion of miR-107 altered the
tendency of the miRNA to target the CDS versus
the 30-UTR. To convey the data more speciﬁcally, the
15 strongest AGO-enriched PmiTs of miR-107, miR-107
MUT1 and miR-107 MUT2 were further analyzed. Shown
in Figure 3 are the number of 50 seed (anti-sense) se-
quences for miR-107, MUT-1 and MUT-2 miRNAs, in
the target mRNAs’ 50-UTR, CDS and 30-UTR. Note
that as expected from Table 1, there are many miR-107
seed anti-sense sequences (UGCUGC) in the CDS of the
strongest miR-107 PmiT-AGO targets. However, seed se-
quences were not enriched in the CDS of miR-107MUT2
targets; miR-107MUT2 has the same seed sequence as
miR-107 but a mutated 30 portion of the miRNA. In
miR-107MUT-2, there are new mRNAs recruited into
the anti-AGO RIP-Chip such as ASB1, KIAA0247 and
FGFRL1 which have many miR-107 seed sequences in the
30-UTR rather than the CDS. In contrast, for
miR-107MUT1, which has a different seed sequence yet
shares the same 30 portion with miR-107, 8 of the top 15
PmiT-AGOs have MUT-1 seed sequences enriched in the
CDS, and none in the 30-UTR. This detailed analysis
provides speciﬁc examples of how altering the 30 portion
of miR-107 leads to a change in the normal tendency of
miR-107 to target mRNAs’ CDS.
Whereas Table 1 and Figure 3 focus on the strongest
PmiT-AGO mRNAs, we sought to better understand the
tendency of miRNA seed sequences to be present in less
strong targets, both for PmiT-AGOs and for PmiT-Lys
mRNAs. We previously described RIP-Chip assays
related to miR-107 (22), but the data presented here
(including the miR-107 results) are the results of entirely
different experiments. New analyses (Figures 5–7) show
data for miR-103 and miR-320, a control physiological
miRNA. Complete data referent to all the RIP-Chip and
lysate RNA microarray results (a total of 54 microarrays)
can be found in Supplementary Figure S1.
In a manner almost identical to miR-107, miR-103
PmiT-AGO mRNAs show increased density of 6-mer
sequences corresponding to the miRNA nucleotides 2–7
in the CDS, but not in the 30-UTR (Figure 4). There is also
a tendency for other members of miR15/107 group to
have enriched seeds in the CDS among PmiT-AGO
mRNA targets (Table 1 and Supplementary Figure S5).
In addition to stable association with AGO proteins, it
is also known that many target mRNA are degraded
following miRNA targeting (27). Enrichment was not
seen in seed sequences among miR-103 (Figure 5) or
miR-107 (data not shown) knockdown mRNAs
Table 1. Presence of miRNA seed complementary sequence in the top 100 PmiT-AGO targets relative to controls
miR-103 miR-107 miR-16 miR-195 miR-320 MUT1 MUT2 miR-15b*
Seed anti-sense UGCUGC UGCUGC GCUGCU GCUGCU AGCUUU GCGACG UGCUGC UGAUUC
50-UTR 1.38±0.10 0.57±0.04 1.01±0.06 0.85±0.05 0.82±0.06 2.58±0.16 0.91±0.07 0.90±0.13
CDS 2.65+0.07 1.94±0.04 1.38±0.04 1.67±0.05 1.31±0.05 3.44+0.09 1.41±0.03 1.76±0.04
30-UTR 1.41±0.05 1.20±0.04 1.09±0.04 1.18±0.04 1.23±0.03 1.42±0.25 1.89±0.06 1.63±0.35
Ratio CDS:30-UTR 1.88 1.62 1.26 1.41 1.07 2.43 0.75 1.08
Ratio of the complementary seed density (seeds/1000nt) in the top 100 targets for EACH miRNA, in the 50-UTR, CDS, and 30-UTR of those
PmiT-AGO mRNAs, relative to the densities of those seed complementary sequences in randomized control mRNAs’ 50-UTR, CDS and 30-UTR.
The numbers in the table represent the seed density ratio of targets to controls±standard deviation of the ratios from multiple rounds of calculation
(see ‘Materials and Methods’ section for details).
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PmiT-Lys shows a tendency of seed sequence enrichment
in 30-UTR (Figure 6). In other words, unlike for miR-107,
miR-320 tends to induce ‘knockdown’ of mRNAs that
harbor miR-320 seed sequences in the 30-UTR. One
feature shared by miR-103, miR-320 and the other
miRNAs is that seed sequences are enriched in thousands
of lower strength PmiTs (Figures 4 and 6), conﬁrming that
107/M2 seeds: UGCUGC M1 seeds: GCGACG
5'utr CDS 3'utr 5'utr CDS 3'utr
Top
miR-
107
targets
(PmiT-
AGO)
GRN 1 18 0 0 0 0
BOLA3 0 1 0 0 0 0
SLC29A3 0 1 1 0 0 0
RPLP0 0 6 0 0 0 0
C22orf13 0 4 1 0 0 0
NINJ1 0 2 1 0 0 0
IER3IP1 0 2 0 0 0 0
GOT2 0 2 2 0 0 0
LDOC1 0 3 5 0 0 0
CES1 0 2 0 0 0 0
AMAC1 0 1 0 0 0 0
KRTAP5-4 0 13 0 0 0 0
FOXA3 0 1 1 0 0 0
TM4SF19 0 1 0 0 0 0
RSU1 0 0 1 0 0 0
107/M2 seeds: UGCUGC M1 seeds: GCGACG
5'utr CDS 3'utr 5'utr CDS 3'utr
Top
mut1
targets
(5’ seed 
mutated)
RAB11A 1 0 1 1 1 0
GPR89B 0 2 0 0 0 0
SLC29A1 0 2 0 0 0 0
MIER2 0 0 0 0 0 0
FIZ1 0 4 0 0 1 0
OCEL1 0 0 0 0 0 0
PLOD1 0 2 0 0 1 0
ERCC8 0 0 0 0 0 0
C20orf43 2 1 0 0 1 0
UFC1 0 0 0 0 1 0
NFATC4 0 2 2 0 1 0
TRIM62 2 1 1 0 1 0
BNIP1 0 0 1 0 0 0
CEBPB 0 1 0 1 1 0
CISD1 0 1 1 1 0 0
107/M2 seeds: UGCUGC M1 seeds: GCGACG
5'utr CDS 3'utr 5'utr CDS 3'utr
Top
mut2
targets
(3’ seq 
mutated)
GRN 1 18 0 0 0 0
RPLP0 0 6 0 0 0 0
CSNK1G2 0 1 2 0 1 0
C12orf57 0 3 0 0 1 0
ASB1 0 0 10 0 0 0
C14orf83 0 0 1 0 0 0
PRAMEF12 0 3 0 0 0 0
KIAA0247 0 1 10 0 0 0
RPS27 0 0 0 0 0 0
FAM69B 0 4 0 0 0 0
C6orf145 0 0 2 0 2 0
FGFRL1 0 6 10 0 1 0
CTTNBP2 0 12 0 0 1 0
GOT1L1 0 0 0 0 0 0
RNMTL1 0 1 0 0 0 0
Figure 3. Top 15 targets (according to anti-AGO co-IP experiments) for miR-107, miR-107 MUT1 (50 portion mutated) and miR-107 MUT2
(30 portion mutated). Note that the miR-107 and miR-107 MUT2 have the same 50-seed sequence (GCAGCA which is complementary to
UGCUGC on the mRNA), but miR-107 MUT1 has a different 50 seed (CGUCGC). The number of those seed sequences in the 50-UTR, CDS/
open reading frame and 30-UTR for each of the targets is shown. Note that for the top 15 miR-107 targets, miR-107 seed sequences tend to be found
in the CDS. For miR-107 MUT1, which has a completely different 50-seed sequence, that seed sequence is found in the CDS of 8/15 top 15 targets
(versus 0/15 for top 15 miR-107 targets). In contrast, miR-107 MUT2 has the same 50-seed sequence as miR-107, but there is a remarkable tendency
among the top 15 targets of miR-107 MUT2 to include mRNAs with the miR-107 seed sequence in the 30-UTR instead of the CDS. These data
appear to indicate that the 30 portion of miR-107 may be directing the miRNA to target CDS rather than the 30-UTR.
Nucleic Acids Research, 2011,Vol.39, No. 18 8167a miRNA’s nucleotides 2–7 exert an important role in
targeting for many hundreds of mRNAs per miRNA.
In contrast to many previously reported miRNAs such
as miR-124 that predominantly target the 30-UTR (22,28),
the miR-103/107 family preferentially binds to the CDS of
the target transcript. As stated above, there was no pref-
erence for CDS targeting when the 30-end of miR-107 was
mutated (i.e. MUT2). This indicates that the 30 portion of
miR-107/103 may play a role in CDS target determin-
ation. To test this hypothesis, word analyses were per-
formed testing complementary sequences to the 30 12nt
of miR-103, miR-107 as well as two mutated miRNAs
derived from miR-107 (MUT1 and MUT2), to assess
whether there is any enriched 30-end pairing sequences in
the target sites in the CDS. The result is summarized in
Table 2. In this sequence analysis, the strongest putative
targets, as identiﬁed in either the anti-AGO co-IP or lysate
fraction, were included. Following miR-107 transfection,
21 of the 50 selected transcripts from the IP fraction
contain pentamer words in the target site that pair per-
fectly to the 30 portion of miR-107, and this observed word
enrichment was statistically signiﬁcant (P=0.04 by simu-
lation test). The result was similar for miR-103 targeted
transcripts from the IP fraction (trend with P=0.09). In
contrast, there was no signiﬁcant enrichment of the 30
portion matching sequences in the mutated miRNAs
(MUT1 and MUT2) or the transcripts identiﬁed from
the lysate fraction.
To further determine whether there are any speciﬁc
sequence motifs in the 30 portion of miR-107 that are
involved in target recognition, we compared the 30-end
sequences of miR-107 and MUT2. To focus our analysis
on the 30 portion of miR-107, we only included 110 tran-
script sequences that are signiﬁcantly enriched in the IP
fraction of miR-107, but not that of MUT2. The enrich-
ment of these genes is likely determined by the 30-end of
the miR-107 since the only difference between miR-107
and MUT2 is the mutated bases from the 30-end. In the
30 portion of miR-107, we found a sequence motif AGCC
CUGU that was signiﬁcantly enriched for these 110 genes.
Within this motif, three adjacent pentamer words were
signiﬁcantly enriched, with anti-sense sequences found in
Y axis:
mRNA enrichment in Anti-AGO co-IP  
after miRNA transfection (N=3 each):
([mRNA] in co-IP after miR-103 transfections)
divided by
([mRNA] in co-IP after NEGctrl transfections)
X-axis:
3000 mRNAs, arranged in order of enrichment 
in Anti-AGO co-IP after miR-103 transfections
X Axis:
Same as in A.
(each data point a 
group of 50 mRNAs)
Y axis:
Average miR-103 
seed sequences per 
1,000 nts, in 5’UTR, 
CDS, and 3’UTR.  
Seed sequence ( # / per 1000nts) in PmiT-AGOs: miR-103
X axis:
mRNAs ordered
by degree of 
enrichment in 
Anti-AGO co-IP
after miR-15b*
transfection.
Y axis:
As above 
(miR-103 seeds).
A
B
C
1                    1000                    2000                3000
1                    1000                    2000                3000
1                      1000                       2000           3000
Figure 4. miR-103 seed sequences are highly enriched in open reading
frame (CDS) of targets. As for miR-103, the strongest miR-103 targets
are those that are enriched for the complementary 50-seed sequence in
the CDS. These data correlate closely with results previously reported
(22). To visualize the correlation between enrichment in the Anti-AGO
Co-IP and the seed sequence densities in the 50-UTR, CDS and
30-UTR, we ﬁrst arranged the mRNAs according to the enrichment
in the anti-AGO Co-IP (A). Here one sees the top 3000 mRNAs in
the order of the average expression levels detected on the microarray
using RNA from the Anti-AGO Co-IP RNA, relative to the transfec-
tion using the NEG-CTRL miRNA (N=3 each). This same order of
mRNAs was used for the chart in B, which shows the miR-103 50
complementary seed densities in 50-UTR, CDS and 30-UTR. The
mRNAs are binned with each data point representing the average
seed densities per 1000nt for 50 different mRNAs. Note that the
most-enriched 50 mRNAs (red arrow) have by far the highest miR-
103 seed densities in the CDS. However, there remains some degree of
enrichment for miR-103 50-seed sequences even among the less-enriched
mRNAs (orange arrow). In contrast, when the mRNAs are sorted
randomly (C, where mRNAs are sorted according to the enrichment
following miR-15b* transfection), there is lower miR-103 seed se-
quences in the 50-UTR, CDS and 30-UTR alike.
X axis:
3000 mRNAs, arranged in order of how much
they are decreased in cell lysate (total mRNA) after 
miR-103 transfection relative to control miRNA 
transfection, and in groups of 50 mRNAs (leftward are 
most decreased in lysate following miR-103 
transfection).
Y axis :
Number of 
miR-103 seed 
sequences per 
1,000nts in the 
5’UTR, CDS, and 
3’UTR.
1                  1000                2000                  3000
Seed sequence ( # / per 1000nts) in PmiT-Lys: miR-103
Figure 5. Enrichment of 50 miRNA seed sequences for miR-103 in
50-UTR, CDS or 30-UTR does not correlate with decreased mRNA
in the lysate. Across all the evaluated mRNA, there is no evidence
that for miR-103 (or miR-107, data not shown) that mRNAs
‘knocked down’ in the lysate after miRNA transfection correlate to
those mRNAs with 50-seed sequences enriched in 50-UTR, CDS or
30-UTR. In this case, the mRNAs are ordered (x-axis) based on the
degree of decrease in the lysate following miR-103 transfection.
8168 Nucleic Acids Research, 2011,Vol.39, No. 18the target sites in 14, 16 and 18 target transcripts for three
pentamer words, respectively (Table 3). Combined
together, 33 of the 110 target transcripts contain anti-sense
pentamer words (any one of the four pentamers within A
GCCCUGU) in the target sites, and this observation was
statistically signiﬁcant (P=0.008 by simulation test).
DISCUSSION
RIP-Chip and miRNA transfection experiments focusing
on miR-15/107 gene group members show that individual
miRNAs follow idiosyncratic ‘binding rules’. We conﬁrm
that miRNA 50 seeds appear to be critical targeting deter-
minants. Yet, as shown previously (4), the 30 portions of
miRNAs also appear to contribute to target binding. We
also provide word analyses showing pentamers recognized
by miRNA 30 sequence elements in strong miR-107
targets. The current study provides the ﬁrst evidence
that the 30 portion of miR-103/7 appears to play a role
in causing miRNAs to bind preferentially to CDS of target
mRNAs (see Figure 7 for an overview). Transfections with
a custom-synthesized miR-107 duplex produced mRNA
proﬁles (BACE1 and GRN) in lysates and anti-AGO
co-IPs that were similar to the commercial siRNA-like
miRNA transfection reagents. Collectively, these data
provide a large new repository of information about
AGO-associated and ‘knocked down’ mRNA targets
related to the miR-15/107 gene group (23). These data
demonstrate the importance of evaluating individual
miRNAs experimentally instead of relying on universal
prediction algorithms before the full complexity of
miRNA ‘binding rules’ is understood.
A focus of this study is the miR-15/107 group of
miRNA genes (23). Although there are common
sequence elements and overlapping functions among
these vertebrate-speciﬁc genes, the evolutionary record is
as yet inadequate to term them a true ‘gene family’.
Members of this group of miRNA genes are highly ex-
pressed in every human cell evaluated to date, and the
genes are increasingly appreciated to serve key functions
including cell division, metabolism, stress response and
angiogenesis (23). These genes have also been implicated
in human cancers, cardiovascular disease and neuro-
degenerative diseases. For example, downregulation of
multiple miR-15/107 gene group members has now been
documented in Alzheimer’s disease (25,29–31).
We have previously validated our observation that
miR-107 targets mRNAs through the CDS (19,22,23,32).
In the current study, we ﬁnd that multiple miR-107
paralogs target the GRN mRNA, which has implications
X axis:
miR-320 targets
sorted by
enrichment in 
anti-AGO co-IP 
(PmiT-AGO)
X axis:
miR-320 targets
sorted by
mRNA lysate
(“knock-down”;
PmiT-Lys)
X axis:
miR-320 targets
(PmiT-AGO)
sorted according
to miR-15b
targets (i.e.
randomly)
A
B
C
Y axis (A-C) = miR-320 seed sequences/1000 nts
in 5’utr, CDS, and 3’UTR (groups of 50 mRNAs)
1                  1000                2000                  3000
1                  1000                2000                  3000
1                  1000                2000                  3000
Figure 6. Enrichment of 50 miRNA seed sequences for miR-320 in the
30-UTR of targets correlates with decreased mRNA levels for those
targets in the cell lysates. For miR-320, unlike miR-103 or miR-107,
there is robust evidence that the seed sequences in the 30-UTR (as
opposed to in the CDS) play a strong role in determining the
miRNA/mRNA targeting. Also unlike miR-103 and miR-107,
miR-320 transfections appear to result in target knockdown. Note
that the seed sequences that are disproportionately found in the
Anti-AGO Co-IP enriched miRNAs (A) and also the mRNAs
knocked down in the lysate after miR-320 transfection (B), correspond
to seed sequences in the 30-UTR (green triangles). However, if sorted
randomly, (C, where mRNAs are sorted according to the enrichment
following miR-15b* transfection) the same tendencies are not seen.
Thus, there is speciﬁc 30-UTR enrichment of miR-320 complementary
50 seeds that correspond speciﬁcally to those mRNAs that are most
enriched in the Anti-AGO Co-IP and also the mRNAs that are most
decreased in the lysate after miR-320 transfection.
Table 2. Enrichment of the anti-sense miRNA 30 portion sequences in the CDS of putative target transcripts
IP fraction
(PmiT-AGO)
Lysate fraction
(PmiT-Lys)
miR-107 MUT1 MUT2 miR-103 miR-107 MUT1 MUT2 miR-103
Number of genes 21 6 13 25 10 5 8 11
P-value 0.04 0.24 0.27 0.09 0.22 0.26 0.50 0.16
Nucleic Acids Research, 2011,Vol.39, No. 18 8169for neurodegenerative diseases and cancer (24,33). It is
hoped that the complete set of data will be of use to
other researchers in better understanding the intriguing
group of miRNAs that includes miR-16, miR-103,
miR-107 and miR-195.
Research from many laboratories has now conﬁrmed
that the CDS of mRNAs can be, and often is, targeted
by miRNAs as summarized by a recent review (6). In
high-throughput, direct experimental evaluation of
miRNA target with ‘HITS-CLIP’ in mouse brain, some
25% of miRNA target sequences resided in open reading
frames of targeted mRNA (33). The biochemical deter-
minants of CDS targeting are not ﬁrmly established.
There has been indication that the tendency for particular
miRNAs to target the 30-UTR instead of the CDS was due
to active translation in the CDS physically dislodging the
miRNP (34), to the presence of upstream AUG sequences
(35), or to the relative inability for CDS sequences to
recruit cap-dependent translational inhibition (36). Just
as the 30-UTR is not the only part of an mRNA that a
miRNA may target, it has also been shown that the 50 seed
portion of miRNAs is not the only determinant of target-
ing from the miRNA side. For example, Shin et al. (37)
showed that the importance of central pairing miRNA
sites for miRNA targeting. However, we know of no ex-
perimentally validated explanation as to why the 30
portion of miRNAs helps to confer its tendency to bind
to the CDS versus the 30-UTR. The biochemical basis for
this effect is a topic of active study in the Nelson
laboratory.
Prior studies have concluded that miRNAs function
through many different mechanisms. A recent paper
showed data to indicate that regulation by three particular
miRNAs (miR-1, miR-155 and miR-223) is achieved
through knocking down the mRNA levels of these
miRNAs’ targets in HeLa cells (27). These data do not
include members of the miR-15/107 gene group and so
our results are not in conﬂict with them. We found previ-
ously that for miRNAs outside the miR-15/107 gene
group—for example, miR-124 and miR-320—the data is
quite compatible with 30-UTR targeting by miRNAs
leading to mRNA degradation (22). We also continue to
ﬁnd evidence that some miR-107 targets (BACE1) may be
targeted via the 30-UTR and act through mRNA degrad-
ation: BACE1 mRNA is decreased in lysates following
miR-107 transfection, protein levels are decreased, but
the mRNA is not present in the anti-AGO co-IP (38).
However, this mode of regulation does not appear to be
the case for the large majority of miR-103/7 targets. Our
high-throughput data provide compelling data that
miR-103 and miR-107 seed sequences are neither
enriched in the 30-UTR of co-IP’d targets, nor in the
30-UTR (or CDS) of mRNAs that are downregulated
after miR-103 or miR-107 transfection. This is in
marked contrast to miR-320 for which 30-UTR seed se-
quences are enriched in both co-IP’d targets and also
mRNAs that are downregulated in the lysate following
miR-320 transfection.
There are limitations to the current study. We used
cultured H4 cancer cells, derived from an aneuploid cell
line (21). The miRNP is functional in H4 cells (19), but
there may be currently uncharacterized idiosyncrasies.
Aside from the inherent limitations of the cultured
tumor cells, RIP-Chip is an assay that does not provide
all the information about miRNA:mRNA interactions.
AGO-miRNPs have been shown to exert gene expression
regulation via multiple mechanisms (1,39). For the mRNA
target to be detected by a microarray downstream of the
anti-Ago co-IP, the target mRNA must be stably bound to
the miRNP which is not necessarily expected in all modes
of mRNA translational repression. We attempted to make
up for this problem by also assessing mRNAs
downregulated in the total lysate following miRNA
transfection.
Coding Sequence (CDS) 5’
AAA
5’
AAA
3’ UTR
A
B hsa-miR-107
targets CDS
5’seed              3’portion
miR-107 MUT2: normal 5’ seed, mutated 3’portion, targets 3’UTR 
miR-107 MUT1: mutated 5’seed, 
normal 3’portion, still targets CDS
hsa-miR-320
and  other  miRNAs
target 3’UTR
5’seed
3’
3’
Figure 7. Depiction of some of the novel ﬁndings of the current study.
(A) miR-320, like other miRNAs that we have evaluated previously
(19,22), preferentially recognizes 30-UTR sequences correlating to the
miRNA 50-seed sequence, and is more likely to induce decreased levels
of mRNA targets in the lysates of cells transfected with miR-320. (B)I n
contrast, miR-107 targets the open reading frame/CDS of mRNAs
leading to stable association between AGO and target mRNAs. The
main determinant of target binding is the 50-seed region of miR-107
(red rectangle). However, a miR-107 mutant (MUT-2) with altered 30
portion (purple rectangle) targets the 30-UTR sequences. A different
miR-107 mutant (MUT-1) with altered 50-seed portion still targets the
CDS, but it targets sequences corresponding to the new 50-seed portion
(yellow rectangle). These data indicate the importance of the 50-seed
sequences in determining the particular mRNAs to target, but also
indicate that the 30 portion of miRNAs may help to select whether
the miRNA targets the CDS or 30-UTR.
Table 3. Characteristics of the anti-sense miRNA 30 sequence
AGCCCUGU in miR-107 PmiT-AGO transcripts
Number of occurrence P-value
AGCCC 18 0.010
CCCUG 16 0.021
GCCCU 14 0.032
CCUGU 11 0.074
One of the four 33 0.008
8170 Nucleic Acids Research, 2011,Vol.39, No. 18Another intriguing possibility is that the tendency of
miR-15/107 family of miRNAs to target CDS systematic-
ally is related to sequence elements found most frequently
in physiological CDSs. An exceptional example of how
this might happen is provided by GRN. The CDS of
GRN, across many animal species, contains many iter-
ations of the sequence motif for cysteine–cysteine (UGC
UGC), and this CDS motif is also targeted by the miR-107
seed sequence (24). We do not ﬁnd a straightforward, sys-
tematic pattern of highly represented coding (versus UTR)
sequences correlating with targeting by individual
miRNAs, but this is an area that deserves further analyses.
In summary, analyses of RIP-Chip experiments in H4
cells provided the bases for detailed evaluation of miR-15/
107 group member targets. Like previous studies, we ﬁnd
that the 50 seed of miRNAs is important for target dis-
crimination but the 30 portion of miRNAs also contributes
to miRNA binding. We also describe compelling data that
for the ﬁrst time indicates the 30 portion of miR-103 and
miR-107 contributes to these miRNAs’ tendency to target
mRNAs’ CDS. These data do not deny or contradict
ﬁndings with other miRNAs. However, these data surely
provide new indications that miRNA biology deﬁes simple
formulas and doctrines. Apparently, members of the
miR-15/107 gene family operate through some biochem-
ical mechanisms that are somewhat distinct from the
handful of miRNAs that were previously characterized
in detail.
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